GLFD is mentioned by Tracy as one of his Neuroscience picks for 1997....
RYE, N.H.--(BUSINESS WIRE)--Jan. 16, 1997--NeuroInvestment today announced
its 1997 Recommended List, as was previously released to subscribers in the
January issue. These are the neuropharmaceutical companies that will
outperform the market over the next 12 months. The average gain for
NeuroInvestment's Recommendations from 7/1/95-12/31/96 was 112%:
1) Interneuron (IPIC: recommended @ $10.31); Redux sales will grow, and we
expect successful completions of Phase III trials for both citicoline and
bucindolol over the next six months, both of which are going to be major
drugs for large-scale needs.
2) Guilford (GLFD: recommended @ $10.57); The target is 35 due to Gliadel's
launch for brain cancer, plus promising programs in neuroimmunophilins and
neuroprotection.
3) Neurex (NXCO: recommended @ $2.00); Approval for Corlopam and the
year-end completion of SNX-111's trials will bring Neurex to at least our
price target of 28.
4) Gliatech (GLIA: recommended @ $8.25); Gliatech's growing European
revenues for their surgical adhesion products and US filings for FDA
approval will bring the stock to 20.
5) Cambridge Neuroscience (CNSI: recommeded @ $9.50) will complete its
Phase III trial for Cerestat in head trauma this year; positive data will
bring the stock to at least 25.
6) Cephalon (CEPH: recommended @ $25.75) benefits from the failure of
Amgen/Regeneron's competing drug for ALS. The FDA will approve Myotrophin
expeditiously, through Provigil for narcolepsy may not be reviewed this
year. The cost of buying out its Myotrophin partners limits the target to
50.
7) Cypros (CYPR: recommended @ $5.38) will continue to unveil data from a
series of Phase II studies, and will launch two or three Phase III trials
for its promising lead compounds. The price target is 10.
Added to the list are:
8) Cortex (CORX) returns to the List having resolved the financial crisis
which was so worrisome this past summer. With clinical data for its novel
lead compound coming mid-year in both Alzheimer's (for which it has a
unique mode of action addressing the basic process of memory formation) and
schizophrenia, the price target is 11.
9) Neurobiological Technologies (NTII) suffered a setback in its rheumatoid
arthritis program, which means that it is now very cheap, considering its
pipeline of drugs in development for pain, AIDS-dementia, and edema. Our
price target is 6.
Other companies who are strong candidates for the List include Cyto
Therapeutics (CTII), CoCensys (COCN), and Diacrin (DCRN).
"The neuroscience sector had a lackluster year in 1996, as did biotech in
general," said Dr. Harry Tracy, publisher of NeuroInvestment. "However,
many of these companies have made striking progress towards offering
effective, commercializable products. 1997 is going to see dramatic
developments in the generation of new treatments for such major disorders
as stroke, head trauma, and Alzheimer's. The recent failure of Regeneron's
drug for ALS is a reminder of how difficult it is to deliver growth factors
effectively, but says nothing about the prospects for the sector as a
whole.
"Biotech is in the first stage of what ultimately is going to be a 10 to 15
year cycle of drug development which will revolutionize medicine. Since
many of the most destructive and hitherto untreatable diseases are
neurological disorders, the neuroscience sector is going to be at the
forefront of this transformation. 1997 should be a solid year with 50-100
percent gains for the best companies in the sector. We expect that 1998
will be even better, and the hierarchy of companies considered 'first-tier'
will be both much larger and quite different than it is today."
A one-year subscription to NeuroInvestment is $295, a two-year subscription
is $550. A 3-month trial subscription is $90. NeuroInvestment can be
reached at P.O. Box 458, Rye, NH 03870. Phone: 603-964-9640; Fax:
603-964-7561; E-Mail: neuroinv@nh.ultranet.com . |
